Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01551797 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.

A Phase 1 study of Pain, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT01551797 is a Phase 1 study of Pain that has completed, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01551797, a Phase 1 study of Pain, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.

Conditions Studied

Interventions

  • DRUG Paracetamol 500 mg
  • DRUG Paracetamol 1000 mg
  • DRUG Paracetamol 750 mg

Study Locations (1)

Washington

  • Charles River Clinical Services Northwest, Inc. - Tacoma

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2010-05
Est. Completion 2010-10
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01551797

The ClinicalTrials.gov registry entry for NCT01551797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Paracetamol 500 mg is the first listed.

NCT01551797 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01551797 about?

NCT01551797 is a clinical study titled "A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.". This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.

What is the current status of trial NCT01551797?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-05. Estimated completion is 2010-10.

What conditions does trial NCT01551797 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT01551797?

The interventions under investigation include: Paracetamol 500 mg (DRUG), Paracetamol 1000 mg (DRUG), Paracetamol 750 mg (DRUG).

Who is sponsoring clinical trial NCT01551797?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01551797 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.